ProPhase Labs (NASDAQ:PRPH) released its earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, Bloomberg Earnings reports. ProPhase Labs had a negative net margin of 8.88% and a negative return on equity of 3.81%. The business had revenue of $2.44 million for the quarter.

Shares of NASDAQ PRPH traded up $0.04 during trading hours on Thursday, hitting $3.03. The stock had a trading volume of 4,129 shares, compared to its average volume of 18,106. The stock has a market cap of $34.51 million, a price-to-earnings ratio of 3.88 and a beta of 0.09. ProPhase Labs has a 52 week low of $2.03 and a 52 week high of $6.64.

Separately, TheStreet raised ProPhase Labs from a “d+” rating to a “c-” rating in a research note on Wednesday, November 7th.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at

About ProPhase Labs

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Featured Article: The Discount Rate – What You Need to Know

Earnings History for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.